Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Tff Pharmaceuticals Inc's Business Segments
Tff Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 1
Regions Reported
-
Tff Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Feasibility54.8%
- Grant45%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Feasibility | $ 0 | 54.8% |
| Grant | $ 0 | 45% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Tff Pharmaceuticals Inc
TFF Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on the development of innovative drug products using its proprietary Thin Film Freezing (TFF) technology. The company was founded in 2011 and is headquartered in Austin, Texas.
TFF Pharmaceuticals aims to improve the solubility and bioavailability of poorly water-soluble drugs by creating dry powders that can be reconstituted into various dosage forms, including films, pellets, and tablets. Their TFF technology platform enables the transformation of drugs into a stable, high-concentration powder form without the need for additional excipients or complex manufacturing processes.
One of the key advantages of TFF Pharmaceuticals' technology is the ability to eliminate the need for refrigeration during storage and transportation, which is particularly crucial for biologics and other sensitive drugs. This could significantly reduce logistical challenges and costs associated with cold chain management.
The company's approach has the potential to revolutionize the pharmaceutical industry by enhancing the efficacy and patient experience of existing drugs while also enabling the development of new therapeutic options. It has already gained recognition for its innovative technology and has entered into collaborations with several pharmaceutical companies to develop drug formulations using TFF.
TFF Pharmaceuticals has a robust pipeline of drug candidates in various stages of development. Their lead product candidate, Voriconazole Inhalation Powder, is being developed for the treatment of invasive pulmonary aspergillosis, a severe fungal infection. The company has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for this program, indicating the potential for expedited regulatory review and approval.
In addition to Voriconazole, TFF Pharmaceuticals is also developing other drug candidates for the treatment of various respiratory diseases, including pulmonary arterial hypertension and pulmonary fibrosis. The company's broad portfolio reflects its commitment to addressing unmet medical needs within the respiratory field.
TFF Pharmaceuticals is actively engaged in clinical trials to evaluate the safety and efficacy of its drug candidates. These trials are designed to generate the necessary data for regulatory submissions and eventual commercialization. The company is also actively pursuing strategic partnerships and collaborations to accelerate the development and commercialization of its products.
Overall, TFF Pharmaceuticals Inc is a dynamic biopharmaceutical company leveraging its proprietary TFF technology platform to develop innovative drug products. With a focus on improving drug solubility, bioavailability, and stability, the company has the potential to bring about significant advancements in the pharmaceutical industry, particularly in the field of respiratory diseases.
TFF Pharmaceuticals aims to improve the solubility and bioavailability of poorly water-soluble drugs by creating dry powders that can be reconstituted into various dosage forms, including films, pellets, and tablets. Their TFF technology platform enables the transformation of drugs into a stable, high-concentration powder form without the need for additional excipients or complex manufacturing processes.
One of the key advantages of TFF Pharmaceuticals' technology is the ability to eliminate the need for refrigeration during storage and transportation, which is particularly crucial for biologics and other sensitive drugs. This could significantly reduce logistical challenges and costs associated with cold chain management.
The company's approach has the potential to revolutionize the pharmaceutical industry by enhancing the efficacy and patient experience of existing drugs while also enabling the development of new therapeutic options. It has already gained recognition for its innovative technology and has entered into collaborations with several pharmaceutical companies to develop drug formulations using TFF.
TFF Pharmaceuticals has a robust pipeline of drug candidates in various stages of development. Their lead product candidate, Voriconazole Inhalation Powder, is being developed for the treatment of invasive pulmonary aspergillosis, a severe fungal infection. The company has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for this program, indicating the potential for expedited regulatory review and approval.
In addition to Voriconazole, TFF Pharmaceuticals is also developing other drug candidates for the treatment of various respiratory diseases, including pulmonary arterial hypertension and pulmonary fibrosis. The company's broad portfolio reflects its commitment to addressing unmet medical needs within the respiratory field.
TFF Pharmaceuticals is actively engaged in clinical trials to evaluate the safety and efficacy of its drug candidates. These trials are designed to generate the necessary data for regulatory submissions and eventual commercialization. The company is also actively pursuing strategic partnerships and collaborations to accelerate the development and commercialization of its products.
Overall, TFF Pharmaceuticals Inc is a dynamic biopharmaceutical company leveraging its proprietary TFF technology platform to develop innovative drug products. With a focus on improving drug solubility, bioavailability, and stability, the company has the potential to bring about significant advancements in the pharmaceutical industry, particularly in the field of respiratory diseases.
TFF Pharmaceuticals Inc. is a biopharmaceutical company primarily focused on developing and commercializing novel drug delivery platforms using its proprietary Thin Film Freezing (TFF) technology. This technology allows for the transformation of drugs into finely divided particles, which can enhance their solubility and bioavailability, potentially leading to improved therapeutic outcomes. The company’s approach is especially beneficial for drugs that have poor solubility in water, addressing a significant challenge in pharmaceutical development.
Segments
1. Product Development: TFF Pharmaceuticals operates in the pharmaceuticals segment, focusing on the development of therapies for various indications. The company is interested in both novel candidates and repurposing existing drugs to improve their delivery mechanisms through TFF technology.
2. Partnerships and Collaborations: The company engages in strategic partnerships with other biotech and pharmaceutical firms to leverage its TFF technology for various applications. These collaborations may involve joint development agreements or licensing arrangements.
3. Research and Development (R&D): TFF invests heavily in R&D, continuously seeking to innovate and refine its TFF technology for new applications across a broad range of therapeutic areas. This segment plays a crucial role in identifying potential new products and enhancing existing technologies.
Products
TFF Pharmaceuticals primarily focuses on the following product candidates, although specific details may evolve as the company progresses through clinical trials:
1. TXA (Tranexamic Acid): One of the lead candidates, this product is designed to deliver tranexamic acid in a more effective manner, potentially improving its use in treating conditions requiring hemostasis.
2. Cannabinoids and Analgesics: TFF is exploring the use of TFF technology to deliver cannabinoids and other analgesics in a more efficient way, allowing for better patient outcomes in pain management.
3. Vaccines: The company is also investigating the application of TFF technology in the formulation of vaccines, which could lead to enhanced stability and efficacy of various vaccine candidates.
Services
1. Formulation Services: TFF Pharmaceuticals offers formulation services to other companies looking to leverage TFF technology for their own drug candidates. This service streamlines the process of developing stable and effective drug formulations.
2. Technical Support and Licensing: TFF provides technical support for partners utilizing its technology and offers licensing agreements for the use of its TFF platform, helping to advance drug development in various therapeutic areas.
3. Consultation Services: The company may offer consultation in drug formulation and development strategies based on its expertise in the field, assisting companies in optimizing their products for better bioavailability and efficacy.
In summary, TFF Pharmaceuticals Inc. is committed to harnessing its innovative TFF technology to advance drug delivery systems across multiple therapeutic segments. With an extensive focus on product development, collaborative partnerships, and a diverse range of candidate drugs, the company is poised to impact the pharmaceutical industry by enhancing drug solubility and bioavailability.
Segments
1. Product Development: TFF Pharmaceuticals operates in the pharmaceuticals segment, focusing on the development of therapies for various indications. The company is interested in both novel candidates and repurposing existing drugs to improve their delivery mechanisms through TFF technology.
2. Partnerships and Collaborations: The company engages in strategic partnerships with other biotech and pharmaceutical firms to leverage its TFF technology for various applications. These collaborations may involve joint development agreements or licensing arrangements.
3. Research and Development (R&D): TFF invests heavily in R&D, continuously seeking to innovate and refine its TFF technology for new applications across a broad range of therapeutic areas. This segment plays a crucial role in identifying potential new products and enhancing existing technologies.
Products
TFF Pharmaceuticals primarily focuses on the following product candidates, although specific details may evolve as the company progresses through clinical trials:
1. TXA (Tranexamic Acid): One of the lead candidates, this product is designed to deliver tranexamic acid in a more effective manner, potentially improving its use in treating conditions requiring hemostasis.
2. Cannabinoids and Analgesics: TFF is exploring the use of TFF technology to deliver cannabinoids and other analgesics in a more efficient way, allowing for better patient outcomes in pain management.
3. Vaccines: The company is also investigating the application of TFF technology in the formulation of vaccines, which could lead to enhanced stability and efficacy of various vaccine candidates.
Services
1. Formulation Services: TFF Pharmaceuticals offers formulation services to other companies looking to leverage TFF technology for their own drug candidates. This service streamlines the process of developing stable and effective drug formulations.
2. Technical Support and Licensing: TFF provides technical support for partners utilizing its technology and offers licensing agreements for the use of its TFF platform, helping to advance drug development in various therapeutic areas.
3. Consultation Services: The company may offer consultation in drug formulation and development strategies based on its expertise in the field, assisting companies in optimizing their products for better bioavailability and efficacy.
In summary, TFF Pharmaceuticals Inc. is committed to harnessing its innovative TFF technology to advance drug delivery systems across multiple therapeutic segments. With an extensive focus on product development, collaborative partnerships, and a diverse range of candidate drugs, the company is poised to impact the pharmaceutical industry by enhancing drug solubility and bioavailability.